175 related articles for article (PubMed ID: 26188382)
1. Thyroid Hürthle cell tumors: research of potential markers of malignancy.
Donatini G; Beaulieu A; Castagnet M; Kraimps JL; Levillain P; Fromont G
J Endocrinol Invest; 2016 Feb; 39(2):153-8. PubMed ID: 26188382
[TBL] [Abstract][Full Text] [Related]
2. Immunocytochemical expression of Ki67 and laminin in Hurthle cell adenomas and carcinomas.
Pisani T; Pantellini F; Centanni M; Vecchione A; Giovagnoli MR
Anticancer Res; 2003; 23(4):3323-6. PubMed ID: 12926070
[TBL] [Abstract][Full Text] [Related]
3. Pathologic features, proliferative activity, and cyclin D1 expression in Hurthle cell neoplasms of the thyroid.
Erickson LA; Jin L; Goellner JR; Lohse C; Pankratz VS; Zukerberg LR; Thompson GB; van Heerden JA; Grant CS; Lloyd RV
Mod Pathol; 2000 Feb; 13(2):186-92. PubMed ID: 10697277
[TBL] [Abstract][Full Text] [Related]
4. Genomic dissection of Hurthle cell carcinoma reveals a unique class of thyroid malignancy.
Ganly I; Ricarte Filho J; Eng S; Ghossein R; Morris LG; Liang Y; Socci N; Kannan K; Mo Q; Fagin JA; Chan TA
J Clin Endocrinol Metab; 2013 May; 98(5):E962-72. PubMed ID: 23543667
[TBL] [Abstract][Full Text] [Related]
5. Factors predicting malignancy of Hürthle cell tumors of the thyroid: influence on surgical treatment.
Pisanu A; Sias L; Uccheddu A
World J Surg; 2004 Aug; 28(8):761-5. PubMed ID: 15457355
[TBL] [Abstract][Full Text] [Related]
6. Does Hurthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine-needle aspiration?
Pu RT; Yang J; Wasserman PG; Bhuiya T; Griffith KA; Michael CW
Diagn Cytopathol; 2006 May; 34(5):330-4. PubMed ID: 16604553
[TBL] [Abstract][Full Text] [Related]
7. Somatic and germline mutation in GRIM-19, a dual function gene involved in mitochondrial metabolism and cell death, is linked to mitochondrion-rich (Hurthle cell) tumours of the thyroid.
Máximo V; Botelho T; Capela J; Soares P; Lima J; Taveira A; Amaro T; Barbosa AP; Preto A; Harach HR; Williams D; Sobrinho-Simões M
Br J Cancer; 2005 May; 92(10):1892-8. PubMed ID: 15841082
[TBL] [Abstract][Full Text] [Related]
8. Oncocytic cell tumors of the thyroid: factors predicting malignancy and influencing prognosis, treatment decisions, and outcomes.
Pisanu A; Di Chiara B; Reccia I; Uccheddu A
World J Surg; 2010 Apr; 34(4):836-43. PubMed ID: 20041243
[TBL] [Abstract][Full Text] [Related]
9. Unilateral lobectomy for Hurthle cell adenoma.
Wasvary H; Czako P; Poulik J; Lucas R
Am Surg; 1998 Aug; 64(8):729-32; discussion 732-3. PubMed ID: 9697901
[TBL] [Abstract][Full Text] [Related]
10. [Predictive factors for malignancy in Hürthle-cell thyroid neoplasia. Effect of surgical treatment].
Pisanu A; Aste L; Piu S; Cois A; Uccheddu A
Tumori; 2003; 89(4 Suppl):223-5. PubMed ID: 12903600
[TBL] [Abstract][Full Text] [Related]
11. The RET/PTC oncogene is frequently activated in oncocytic thyroid tumors (Hurthle cell adenomas and carcinomas), but not in oncocytic hyperplastic lesions.
Chiappetta G; Toti P; Cetta F; Giuliano A; Pentimalli F; Amendola I; Lazzi S; Monaco M; Mazzuchelli L; Tosi P; Santoro M; Fusco A
J Clin Endocrinol Metab; 2002 Jan; 87(1):364-9. PubMed ID: 11788677
[TBL] [Abstract][Full Text] [Related]
12. Hürthle cell tumors: applying molecular markers to define a new management algorithm.
Maxwell EL; Palme CE; Freeman J
Arch Otolaryngol Head Neck Surg; 2006 Jan; 132(1):54-8. PubMed ID: 16415430
[TBL] [Abstract][Full Text] [Related]
13. Older age and larger tumor size predict malignancy in hürthle cell neoplasms of the thyroid.
Zhang YW; Greenblatt DY; Repplinger D; Bargren A; Adler JT; Sippel RS; Chen H
Ann Surg Oncol; 2008 Oct; 15(10):2842-6. PubMed ID: 18665423
[TBL] [Abstract][Full Text] [Related]
14. [Thyroidal oxyphilic tumors].
Sabo R; Zohar Y; Schwartz A; Segal K
Harefuah; 1994 Feb; 126(4):183-6, 240. PubMed ID: 8168757
[TBL] [Abstract][Full Text] [Related]
15. [Hürthle cell tumors: personal experience].
De Toma G; Gabriele R; Sgarzini G; Plocco M; Campli M; Sambuco L
G Chir; 1995 May; 16(5):223-6. PubMed ID: 7654499
[TBL] [Abstract][Full Text] [Related]
16. Tumor size predicts malignant potential in Hürthle cell neoplasms of the thyroid.
Sippel RS; Elaraj DM; Khanafshar E; Zarnegar R; Kebebew E; Duh QY; Clark OH
World J Surg; 2008 May; 32(5):702-7. PubMed ID: 18224463
[TBL] [Abstract][Full Text] [Related]
17. Accumulation of p27(kip1) is associated with cyclin D3 overexpression in the oxyphilic (Hurthle cell) variant of follicular thyroid carcinoma.
Troncone G; Iaccarino A; Russo M; Palmieri EA; Volante M; Papotti M; Viglietto G; Palombini L
J Clin Pathol; 2007 Apr; 60(4):377-81. PubMed ID: 16798934
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of molecular expression profiles of Hürthle cell tumors of the thyroid gland analyzed via tissue microarrays.
Hoos A; Stojadinovic A; Singh B; Dudas ME; Leung DH; Shaha AR; Shah JP; Brennan MF; Cordon-Cardo C; Ghossein R
Am J Pathol; 2002 Jan; 160(1):175-83. PubMed ID: 11786411
[TBL] [Abstract][Full Text] [Related]
19. Surgical treatment of Hurthle cell tumors of the thyroid.
Chao TC; Lin JD; Chen MF
World J Surg; 2005 Feb; 29(2):164-8. PubMed ID: 15650796
[TBL] [Abstract][Full Text] [Related]
20. E2F-1 transcription factor is overexpressed in oxyphilic thyroid tumors.
Volante M; Croce S; Pecchioni C; Papotti M
Mod Pathol; 2002 Oct; 15(10):1038-43. PubMed ID: 12379749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
